Ulimorelin

Ulimorelin is a ghrelin agonist developed by Tranzyme Pharma and Novartis for the treatment of gastrointestinal disorders. It is currently in clinical trials.

History

Ulimorelin was first developed by Tranzyme Pharma and Novartis. The drug is currently in the clinical trial phase.

Mechanism of Action

Ulimorelin works by mimicking the action of ghrelin, a hormone that stimulates the release of growth hormone and regulates appetite and energy balance. This action can help to improve gastrointestinal motility, which can be beneficial in conditions such as gastroparesis and chronic constipation.

Clinical Trials

Ulimorelin has undergone several clinical trials to assess its safety and efficacy. These trials have shown promising results, with the drug demonstrating a significant improvement in gastrointestinal motility and a good safety profile.

Potential Uses

Ulimorelin has potential uses in a variety of gastrointestinal disorders. It could be used to treat conditions such as gastroparesis, chronic constipation, and other disorders characterized by impaired gastrointestinal motility.

Side Effects

As with any drug, Ulimorelin may cause side effects. These can include nausea, vomiting, and abdominal pain. However, these side effects are generally mild and manageable.

Future Research

Future research on Ulimorelin will focus on further assessing its safety and efficacy in larger patient populations. This research will also aim to identify any potential long-term side effects of the drug.

See Also

• Ghrelin
• Gastrointestinal disorders
• Clinical trials
• Novartis
• Tranzyme Pharma

Ulimorelin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia